Dear classmates, have you noticed the recent wave of transfer in the field of innovative drugs in China, and are you holding ideals and preparing to take action? Do you aspire to stand at the forefront of biopharmaceutical technology and drive world change with the power of innovation? Are you looking forward to joining a team driven by artificial intelligence and big data, dedicated to tackling major health challenges for humanity? Shanghai Lishan Biopharmaceutical Co., Ltd.'s 2025 campus recruitment has officially started! We are looking for you who dare to dream and take action, to join us in writing new legends in the vast ocean of life sciences.   About Lishan Lishan Biotech relies on its profound scientific research accumulation and industrialization experience, driven by artificial intelligence and big data, to build a golden triangle system of "efficient discov...

  On June 19, 2025, at the headquarters building of Douzheng Biotechnology in Changsha, Lishan Biotech and leading domestic CRO enterprise Douzheng Biotechnology officially reached a strategic cooperation to jointly promote the clinical trials of Lishan Biotech's independently developed live biopharmaceutical (LBP) in the field of inflammatory bowel disease (IBD). This cooperation marks a new stage in the clinical exploration of live biopharmaceutical therapy, which is expected to provide safer and more effective innovative therapies for IBD patients worldwide.   Innovative treatment for IBD using LBP biopharmaceuticals Live Biotherapeutic Products (LBP) is an emerging therapy that utilizes live microorganisms to regulate the human microbiota for the treatment of diseases, and is considered the "third generation therapy" after small molecule...

On the morning of May 15, 2025, the Zhangjiang China Medicine Valley Conference Room welcomed a team of evaluation experts led by the Pudong New Area Science and Technology Commission to assess the digital transformation achievements of Shanghai Lishan Biopharmaceutical Co., Ltd. on site. Dr. Zhu Chaoyu, General Manager of Lishan Biotechnology, along with Ms. Guo Yushan, Manager of the Research Project Management Department, Dr. Wang Mengya, Deputy Director of Zhangjiang Live Biopharmaceutical R&D Center, Ms. Song Junmei, Deputy General Manager, Mr. Yang Weikang, Manager of the Production Quality Department, and other team members, participated in the on-site review, which was chaired and reported by Ms. Guo Yushan. Starting from September 1, 2024, Lishan Biotechnology has completed the upgrade and deployment of the Su...

  The change of time sequence gave birth to Huazhang, and spring and Jingming brought good news. On May 9th, 2025, Lishan Biotech Dr. Chen Weijie, Chairman, was awarded the VBEF Annual Innovation Entrepreneur AwardLishan Biotechnology, with its cutting-edge breakthroughs and innovative value in the field of live biopharmaceuticals, has successfully made it onto the list of "2025 Future Medical Top 100" on Arterial Network! This is not only a tribute to the scientific research team's perseverance, but also a full affirmation of the "AI+live biopharmaceutical" innovation track strategy.   As a benchmark for innovation in the healthcare industry, the "Future Medical Top 100" always focuses on non listed companies with the greatest growth potential. The selection of Lishan Biotechnology marks the industry's recognition of its leading position in ...